8-KLeadership Changes

AbbVie Inc. 8-K Report, Executive Changes (Oct 14, 2016)

Filed October 14, 2016For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K report on October 14, 2016, announcing a change in its Vice President, Controller role. Thomas A. Hurwich, after a 33-year tenure, will retire effective February 28, 2017. This marks the end of a long and presumably stable period for this key financial oversight position within the company. Taking over as the new Vice President, Controller will be Robert A. Michael, effective March 1, 2017. Mr. Michael brings extensive experience within AbbVie and its predecessor, Abbott Laboratories, holding various senior financial roles since 1993. His appointment to this critical finance position suggests a continuation of experienced leadership in financial reporting and controls.

Key Highlights

  • 1Thomas A. Hurwich is resigning as Vice President, Controller, effective February 28, 2017, after a 33-year career.
  • 2Mr. Hurwich intends to retire from AbbVie in 2017.
  • 3Robert A. Michael has been appointed as the new Vice President, Controller, effective March 1, 2017.
  • 4Mr. Michael has been an AbbVie officer since 2015 and holds significant experience in treasury and financial planning and analysis.
  • 5Mr. Michael previously held various financial leadership roles at Abbott Laboratories, AbbVie's former parent company.
  • 6The change in Controller is effective in early 2017, indicating a transition period over the next few months.
  • 7The filing confirms the continuity of experienced financial leadership within AbbVie.

Frequently Asked Questions

Thomas A. Hurwich is stepping down as Vice President, Controller, after a 33-year career with the company. His resignation is effective February 28, 2017, and he plans to retire later in 2017.

Robert A. Michael will assume the role of Vice President, Controller, effective March 1, 2017. He has been an AbbVie officer since 2015 and possesses substantial experience in finance roles.

Robert A. Michael has a long history with AbbVie and its former parent, Abbott Laboratories, since 1993. Prior to this appointment, he served as AbbVie's Vice President, Treasurer since 2015 and held previous roles in Commercial Operations and Financial Planning & Analysis within AbbVie, as well as a Division Controller role at Abbott.

The transition will occur in early 2017. Mr. Hurwich's resignation is effective February 28, 2017, and Mr. Michael's appointment is effective March 1, 2017, allowing for a brief overlap or handover period.